CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518987-11-00

Enrollment

Registered

2024-11-27

Start date

2019-06-12

Completion date

Unknown

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADCC, Colorectal Cancer

Brief summary

Activity assessed by RECIST criteria version 1.1

Detailed description

Response duration, PFS will be determined from the date of treatment start until progression., OS will be measured from treatment start until death from any cause., Toxic effects assessed by CTCAE of the National Cancer Institute, version 4.0, June 14, 2010

Interventions

DRUGCETUXIMAB

DRUGFOLINIC ACID

DRUGFLUOROURACIL

DRUGIRINOTECAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Activity assessed by RECIST criteria version 1.1	—

Secondary

Measure	Time frame
Response duration, PFS will be determined from the date of treatment start until progression., OS will be measured from treatment start until death from any cause., Toxic effects assessed by CTCAE of the National Cancer Institute, version 4.0, June 14, 2010	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026